Novavax, Inc. (NASDAQ:NVAX) Shares Bought by NewEdge Wealth LLC

NewEdge Wealth LLC grew its stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 70.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 170,117 shares of the biopharmaceutical company's stock after buying an additional 70,117 shares during the period. NewEdge Wealth LLC owned 0.11% of Novavax worth $1,368,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in NVAX. Creative Planning lifted its position in shares of Novavax by 34.5% during the 3rd quarter. Creative Planning now owns 32,482 shares of the biopharmaceutical company's stock valued at $410,000 after buying an additional 8,339 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Novavax by 38.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 1,598 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in Novavax in the 3rd quarter worth approximately $214,000. Nisa Investment Advisors LLC increased its stake in Novavax by 1,192.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 23,449 shares of the biopharmaceutical company's stock worth $296,000 after acquiring an additional 21,635 shares during the last quarter. Finally, US Bancorp DE increased its stake in Novavax by 3,538.8% in the 3rd quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company's stock worth $155,000 after acquiring an additional 11,961 shares during the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NVAX. BTIG Research initiated coverage on Novavax in a research note on Friday, February 28th. They issued a "buy" rating and a $19.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $19.00 target price on shares of Novavax in a report on Tuesday, December 10th. Finally, TD Cowen upgraded Novavax to a "hold" rating in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $18.00.

Novavax Stock Up 2.7 %

NVAX traded up $0.21 during trading hours on Wednesday, reaching $7.89. 3,811,620 shares of the company's stock traded hands, compared to its average volume of 8,107,752. The firm has a 50-day moving average price of $8.47 and a 200 day moving average price of $9.86. Novavax, Inc. has a 52-week low of $3.81 and a 52-week high of $23.86. The firm has a market capitalization of $1.26 billion, a PE ratio of -3.49, a PEG ratio of 2.85 and a beta of 2.14.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.24. The business had revenue of $88.31 million for the quarter, compared to analysts' expectations of $85.48 million. During the same quarter in the previous year, the firm earned ($1.44) EPS. Equities analysts predict that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Insider Activity at Novavax

In other news, Director Rachel K. King sold 4,150 shares of the business's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares of the company's stock, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James F. Young sold 4,600 shares of the business's stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total value of $39,008.00. Following the completion of the transaction, the director now directly owns 57,160 shares of the company's stock, valued at approximately $484,716.80. The trade was a 7.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock worth $119,641 in the last quarter. 1.00% of the stock is owned by company insiders.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.